Tenet Diagnostics Examines the Role of Pharmacogenomic Testing to Lower Medication Costs and Overall Healthcare Expenditures at New York Health Forum

“Collaboration for Success: Multi-Regional Clinical Development,” May 25, 12:30-5 p.m., Yale Club Manhattan, 50 Vanderbilt Ave., Trumbull Room, 18th floor, New York, NY

KENILWORTH, N.J.--()--Tenet Diagnostics (Tenet), a leader in full-service laboratory and genomic testing that delivers fast, accurate turnaround of test results and exceptional customer service, announces that Scott Howell, M.D., MPH &TM, CPE, chief medical officer, Tenet, will share insights into the role of pharmacogenomics (PGx) testing during the session, “Quality and Tech in Clinical Development”, at the 9th New York Health Forum’s “Collaboration for Success: Multi-Regional Clinical Development.”

“As more physicians gain a better understanding of the role that genes play in individual drug response, there’s been a steady increase in the number of clinical PGx tests performed,” says Dr. Howell. “PGx testing is lowering costs and promoting best treatment selections by avoiding drugs that are not metabolized effectively or creating less than desirable clinical outcomes . This forum is an excellent opportunity for stakeholders to come together to share and learn new ideas surrounding care quality, technology advances and clinical collaboration.”

Industry leaders report that PGx testing for potential adverse drug events (ADEs) or ineffective drug responses may reduce healthcare costs over the long term by diminishing the duration and severity of illness and the costs associated with ineffective treatment and avoidable ADEs.

“PGx testing can be used as a prospective screening tool, to be carried out in the absence of a pre-existing medical condition or to identify potential future problems and prevent them from occurring,” says Dr. Howell. “PGx testing makes it possible to find the right drug and the right dose at the right time.”

About Tenet Diagnostics

A leader in full-service diagnostic laboratory testing, Tenet adapts to clients’ needs and delivers fast, accurate test results. A collaborative industry partner, Tenet serves self-funded employers, insurers and health plans, as well as physician practices, addiction treatment clinics and pain management organizations. Advanced technologies and capabilities, such as pharmacogenomic testing, extend the Tenet commitment to patient-centric care. Tenet is accredited by the College of American Pathologists (CAP) as a certified, full-service medical laboratory. http://www.tenetdiagnostics.com

Contacts

Media:
CPR for Tenet Diagnostics
Brittany Tedesco, 201-641-1911, ext. 14
btedesco@cpronline.com

Release Summary

Tenet Diagnostics Examines the Role of Pharmacogenomic Testing to Lower Medication Costs and Overall Healthcare Expenditures at New York Health Forum

Contacts

Media:
CPR for Tenet Diagnostics
Brittany Tedesco, 201-641-1911, ext. 14
btedesco@cpronline.com